Fanconi Anemia — a complex DNA repair disorder caused by variants in any of 23 genes, where the specific complementation group determines bone marrow transplant conditioning intensity and lifetime cancer surveillance protocol.
Whole genome sequencing evaluates all 23 Fanconi anemia complementation group genes simultaneously — the only practical way to determine which gene is responsible, a distinction that directly affects transplant planning and ongoing cancer management.
Fanconi Anemia
Fanconi anemia (FA) is an autosomal recessive (and one X-linked) DNA repair disorder caused by pathogenic variants in genes encoding any component of the Fanconi anemia-BRCA DNA damage response pathway. FA is genetically heterogeneous — 23 complementation groups have been defined (FANC-A through FANC-V, with additional subgroups), corresponding to 23 distinct genes. FANCA pathogenic variants account for approximately 60-70% of FA cases; FANCC (~10%) and FANCG (~10%) are the next most common. FA affects approximately 1 in 130,000 births, with higher frequencies in specific populations: FANCC c.711+4A>T is common in Ashkenazi Jews (carrier frequency ~1 in 90), and FANCA deletions are enriched in Spanish Roma populations.
FA is characterized by a variable combination of: congenital physical anomalies (thumb/radial ray defects, short stature, café-au-lait spots, renal malformations, cardiac defects — present in approximately 60-75% of patients); progressive bone marrow failure (aplastic anemia, typically presenting in the first decade); and markedly elevated cancer risk — particularly acute myeloid leukemia and head and neck squamous cell carcinoma. The median age of bone marrow failure onset is approximately 7 years. Hematopoietic stem cell transplantation (HSCT) is the only curative treatment for the bone marrow failure and AML risk, but FA patients tolerate standard transplant conditioning chemotherapy and radiation extremely poorly due to DNA repair deficiency — requiring specially designed reduced-intensity protocols.
The specific FA complementation group has direct clinical implications. FANCB is X-linked (the only X-linked complementation group) — carrier females have no elevated cancer risk, but hemizygous males are severely affected. FANCD1 pathogenic variants are biallelic BRCA2 — these patients have the most severe FA phenotype, earliest bone marrow failure, and highest additional cancer risks (medulloblastoma, Wilms tumor). FANCN biallelic pathogenic variants are biallelic PALB2. FANCJ biallelic variants are biallelic BRIP1. This overlap with known hereditary cancer genes has implications for heterozygous family members — carriers of FANCD1/BRCA2, FANCN/PALB2, and FANCJ/BRIP1 have heterozygous cancer risk.
FANCD1 pathogenic variants are biallelic BRCA2 — the most severe FA phenotype with earliest cancer onset including pediatric medulloblastoma and Wilms tumor. Carriers are BRCA2 heterozygotes with elevated breast and ovarian cancer risk.
23 complementation groups require 23 genes evaluated simultaneously. Sequential single-gene or limited panel testing is impractical. Whole genome sequencing resolves all FA genes in a single test, enabling rapid complementation group assignment.
Chromosome breakage testing diagnoses FA — but not which gene, which is needed for transplant planning
The diagnostic gold standard for Fanconi anemia is the chromosome breakage (diepoxybutane or mitomycin C) test, which demonstrates the characteristic FA DNA repair defect but does not identify which complementation group or gene is responsible. Complementation group determination — historically done by cell fusion experiments — is required for HSCT conditioning protocol design (some groups require adjusted protocols), cancer surveillance intensity planning (FANCD1/FANCD2 affect the risk profile), and family cascade testing (to identify which relatives may carry heterozygous cancer susceptibility variants). Whole genome sequencing simultaneously evaluates all 23 FA complementation group genes, providing complementation group assignment rapidly from a single DNA sample.
FA gene heterozygotes in the family may have hereditary cancer risk that requires its own surveillance
Families of FA patients contain obligate heterozygous carriers. When the FA complementation group involves BRCA2 (FANCD1), PALB2 (FANCN), BRIP1 (FANCJ), or BRCA1 (FANCS), heterozygous family members carry hereditary breast and ovarian cancer risk requiring dedicated surveillance. A parent of a FANCD1-affected child who is an obligate BRCA2 heterozygote needs immediate BRCA2-positive hereditary cancer management — annual breast MRI, NCCN surveillance protocols, consideration of risk-reducing surgery. Identifying the FA complementation group from whole genome sequencing directly leads to appropriate hereditary cancer counseling for all first-degree relatives who are obligate carriers.
Your full DNA (not just a part of it)
Traditional genetic testing looks at narrow sets of genes, missing most parts of your genome. We sequence your full genome — every gene and every region between genes.
Comprehensive insights and specialized reports
Easy to read and with answers you and your doctor can act on. Not a file to interpret — 200+ clinical reports, organized by category.
Your test becomes more valuable every year
Your DNA does not change, but genome science is accelerating. Every month, new variant-disease associations are discovered. We validate these findings and update your reports automatically. Your test becomes more valuable every year.
The results doctors bring to their hardest cases.
Forty years of uncertainty. One test.
A patient had spent decades in the UK healthcare system without a diagnosis. Dante data, accepted by NHS clinical teams at Queen Elizabeth University Hospital Glasgow, identified Noonan Syndrome and a RUNX1 leukemia-associated variant that had gone undetected. After 40 years, they finally had an answer.
A complete read delivers a complete picture.
A patient came to Dante to investigate periodic paralysis. Reading the complete genome identified a concurrent hereditary cardiac finding — Brugada syndrome — that their doctor confirmed with an ECG. The result also explained a family member's unresolved cardiac history. One test. Every answer in it.
Sequenced in 2019. The data worked in 2021.
Jennifer sequenced her genome with Dante two years before her breast cancer diagnosis. When treatment began, Dante's pharmacogenomics data showed her prescribed chemotherapy would cause serious adverse effects. Her doctor selected an alternative — and she started effective treatment from day one.
Every genetic question deserves a complete answer.
Whether you are searching for answers today or protecting your health for tomorrow, a complete read of your entire genome is the only place to start.
It runs in your family. Now you can know if it runs in your genes.
Your genome contains inherited variants associated with medical conditions like cardiac, cancer, and neurological. We read all of them — with the clinical depth to give the result meaning.
Learn more →When traditional lab tests say you're fine. And you know you're not.
Standard diagnostic tests check for a pre-selected set of answers. We sequence your full DNA — including parts that no test was designed to check. If the answer is in your genome, we will help you find it.
Learn more →Your diagnosis may be right. Your treatment plan may be incomplete.
Your genes determine which treatments are most likely to work — and which are not. We give your doctor the tools and insights to inform your treatment plan.
Learn more →You want to know before something forces the question.
Some people don't wait for a diagnosis or a family history to act. Whole genome sequencing gives you the complete genetic picture now — so you and your doctor can make informed decisions before anything becomes urgent.
Learn more →You already took a DNA test. Here's what it couldn't tell you.
Most consumer DNA tests read less than 0.1% of your genome. We read all of it.
Learn more →Clinical-grade results. Chosen by individuals, trusted by doctors for their most complex cases.
Dante Genome Test helped specialists at a UK national acute hospital in the identification of Noonan Syndrome and a rare leukemia-associated genetic variant that had gone undetected. That result changed the medical care of the patient.
Accredited by & published in
Common questions about whole genome sequencing.
What is the difference between whole genome sequencing and a targeted genetic test?
Targeted genetic tests — including standard hereditary cancer panels — read a pre-defined list of known variants in a specific set of genes. They are designed to find what they already know to look for. Whole genome sequencing reads your entire genome: all 6 billion base pairs, every gene, every region between genes. A Mayo Clinic study published in JAMA Oncology found that standard testing guidelines missed more than half of patients with inherited cancer mutations. Genome Test does not have a fixed list.
What will I receive when my results are ready?
Your Dante Genome delivers 200+ physician-ready reports organized by clinical category — hereditary cancer, cardiac conditions, rare diseases, pharmacogenomics, carrier status, and more. Reports are delivered to your secure Genome Manager and are formatted for direct clinical use. Your genome data is permanently retained and re-analyzed automatically as science advances.
What happens if a clinically significant variant is found?
If a pathogenic or likely-pathogenic variant is identified, it will be clearly flagged in your physician-ready report with clinical context, published evidence, and recommended next steps. We recommend sharing any clinically significant finding with your physician or a genetic counselor, who can guide decisions about surveillance, risk reduction, or cascade testing for family members.
How is this different from a consumer DNA test like 23andMe or AncestryDNA?
Consumer DNA tests use genotyping chips that read less than 0.1% of your genome — a tiny pre-selected set of common variants. They are optimized for ancestry and population-level traits, not clinical genetic findings. The Dante Genome Test sequences 100% of your genome at 30X coverage, the same standard used in clinical diagnostic settings. The two tests are not comparable in scope, methodology, or clinical utility.
How long does it take to get results, and how are they delivered?
Your collection kit ships within 48 hours of ordering. Once your sample arrives at our CLIA-certified laboratory, sequencing and analysis takes 6–8 weeks. Results are delivered securely to your Genome Manager, where you can access your reports, share them with your physician, and receive automatic updates as new findings are validated against your genome.
We work with patient advocacy groups worldwide.
Dante Labs works with patient advocacy groups of any size — for Fanconi Anemia and other conditions, rare and common. We support groups in any country, including virtual patient advocacy groups.
We can provide customized reports, group discounts, and packages tailored for your members. Please reach out using the form and we'll be in touch within two business days.
- Custom genomic reports for your members
- Group discounts and tailored packages
- Any country — including virtual groups
- Rare and common conditions covered
Message received.
We'll be in touch within 2 business days. To follow up directly: hello@dantelabs.com
One test.
A lifetime of answers.
One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.
Ships within 48 hours · Results in 6–8 weeks
